Status:
ACTIVE_NOT_RECRUITING
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Obesity
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintid...
Eligibility Criteria
Inclusion
- Male or female
- Age 18 years or above at the time of signing the informed consent
- Body mass index (BMI) of ≥ 30.0 kilogram per square meter (kg/m\^2)
Exclusion
- Glycated haemoglobin (HbA1c) ≥ 6.5 % (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening
- History of type 1 or type 2 diabetes mellitus
Key Trial Info
Start Date :
November 27 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 13 2026
Estimated Enrollment :
809 Patients enrolled
Trial Details
Trial ID
NCT06131437
Start Date
November 27 2023
End Date
January 13 2026
Last Update
January 6 2026
Active Locations (46)
Enter a location and click search to find clinical trials sorted by distance.
1
Univ of Alabama Birmingham
Birmingham, Alabama, United States, 35294
2
Chambliss Clinical Trials LLC
Montgomery, Alabama, United States, 36106
3
FDRC
Costa Mesa, California, United States, 92627
4
Diablo Clinical Research, Inc.
Walnut Creek, California, United States, 94598